Molecular therapy for Myocardial Infarction: ZBTB2 (Zinc Finger And BTB Domain Containing 2) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 15/March/2017, 1.00 pm

Natural product therapy for Glaucoma: Berberine, isolated from Berberis aristata, Oregon grape, Hydrastis canadensis (goldenseal), Xanthorhiza simplicissima (yellowroot), and Phellodendron amurense (Amur cork tree) among others, increases Nmnat1 expression, increases NAD+ levels, improves neuroanl dysfunction, and protects against glaucoma via down regulation of its target gene, 14/March/2017, 11.16 pm
March 14, 2017
Natural product-derived antiviral therapy for HIV virus: Sylimarin, isolated from M.Thistle, increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production via up regulation of its target gene, 15/March/2017, 1.33 pm
March 15, 2017
Show all

What they say:  

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for Myocardial Infarction: ZBTB2 (Zinc Finger And BTB Domain Containing 2) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via  up-regulation of PNUTS

Price 50

[easy_payment currency=”USD”]

From Significance of the study to Public Health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

This study provides a small molecule-based therapy for myocardial infarction. ZBTB2, by increasing the expression of its target genes, it may increase the expression of PNUTS (figs.1) . Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1). 

ZBTB2 induces PNUTS expression and protects from myocardial infarction

Figure 1. ZBTB2 may function as a Cardioprotective/insulin sensitizing agent. Mechanistic insights into how ZBTB2 induces the expression PNUTS and Telomerase to promote Cardiac regeneration/survival and insulin sensitivity

Thus, by treating myocardial patients with  ZBTB2 activators, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing ZBTB2 or its activators or   ZBTB2 activators in combination with any of the known drugs that improve myocardial function”  may be used to improve cardiac function after myocardial infarction (fig. 3) 

[easy_payment currency=”USD”]


Details of the research findings

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How   ZBTB2  increases the expression of PNUTS and Telomerase

Amount: $50#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Molecular therapy for Myocardial Infarction: ZBTB2 (Zinc Finger And BTB Domain Containing 2) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via  up-regulation of PNUTS, 15/March/2017, 1.00 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.